QDEL Quidel

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.

Company profile

QDEL stock data



18 Feb 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Quidel earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Mar 21 William J. Ferenczy Common Stock Payment of exercise Dispose F No No 126.39 216 27.3K 5,324
30 Mar 21 William J. Ferenczy Common Stock Option exercise Aquire M No No 0 434 0 5,540
30 Mar 21 William J. Ferenczy RSU Common Stock Option exercise Dispose M No No 0 434 0 1,302
17 Mar 21 William J. Ferenczy Common Stock Sell Dispose S No No 136.0488 2,799 380.8K 5,106
17 Mar 21 William J. Ferenczy Common Stock Sell Dispose S No No 136.0654 4,601 626.04K 7,905
17 Mar 21 William J. Ferenczy Common Stock Option exercise Aquire M No No 15.4 3,910 60.21K 12,506
17 Mar 21 William J. Ferenczy Common Stock Option exercise Aquire M No No 23.41 691 16.18K 8,596
17 Mar 21 William J. Ferenczy NQSO Common Stock Option exercise Dispose M No No 15.4 3,910 60.21K 0
17 Mar 21 William J. Ferenczy NQSO Common Stock Option exercise Dispose M No No 23.41 691 16.18K 1,263
26 Feb 21 Joseph D Jr. Wilkins RSU Common Stock Grant Aquire A No No 0 289 0 289

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

19.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 3 392 -99.2%
Opened positions 1 392 -99.7%
Closed positions 390 0 NEW
Increased positions 1 0 NEW
Reduced positions 1 0 NEW
13F shares
Current Prev Q Change
Total value 1.5B 8.94B -83.2%
Total shares 8.35M 35.26M -76.3%
Total puts 0 635.1K EXIT
Total calls 0 914K EXIT
Total put/call ratio 0.7
Largest owners
Shares Value Change
TROW T. Rowe Price 4.26M $765.64M +0.6%
Brown Capital Management 2.28M $410.04M -1.0%
Larry N Feinberg 1.81M $325.12M NEW
Largest transactions
Shares Bought/sold Change
Vanguard 0 -3.51M EXIT
BLK Blackrock 0 -3.41M EXIT
Larry N Feinberg 1.81M +1.81M NEW
Oracle Investment Management 0 -1.8M EXIT
Fred Alger Management 0 -1.61M EXIT
FMR 0 -1.03M EXIT
STT State Street 0 -906.63K EXIT
ArrowMark Colorado 0 -844.81K EXIT
IVZ Invesco 0 -808.27K EXIT
Wellington Management 0 -803.94K EXIT

Financial report summary

  • The novel coronavirus global pandemic could adversely affect our business operations, financial performance and results of operations, the extent of which is uncertain and difficult to predict.
  • The industry and market segment in which we operate are highly competitive, and intense competition with other providers of diagnostic products or services may reduce our sales and margins.
  • Our operating results are heavily dependent on sales of our COVID-19 and influenza diagnostic tests and if sales or revenues of our COVID-19 or influenza tests decline for any reason, our operating results would be materially and adversely affected.
  • We rely on a limited number of key distributors that account for a significant portion of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.
  • Our results of operations and financial condition may be adversely affected by the financial soundness of our customers and suppliers.
  • We may not achieve market acceptance of our products among physicians, healthcare providers or other customers, and this would have a negative effect on future sales.
  • Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.
  • Unexpected increases in, or inability to meet, demand for our products and services could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.
  • Interruptions in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results.
  • Failures in our information technology and storage systems, including as a result of cyber-security breaches, could significantly disrupt our business or force us to expend excessive costs.
  • We face risks relating to our international sales, including inherent economic, political and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
  • Continuing worldwide political and social uncertainty, including tariffs, trade wars or social tensions, may adversely affect our business and prospects, both domestically and internationally.
  • To remain competitive, we must continue to develop and obtain proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with our products.
  • Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.
  • Our COVID-19 products were approved by the FDA through an EUA and the loss of such authorization could have a material adverse impact on our business, results of operations, financial position and cash flows.
  • Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals, clearances or authorizations, the loss of previously received approvals or other changes to existing laws and regulations that adversely impact our ability to manufacture and market our products.
  • Our contracts with government entities involve future funding, compliance, and possible sanctions risks
  • If one or more of our products is claimed to be defective, we could be subject to claims of liability and harm to our reputation that could adversely affect our business.
  • We use hazardous materials in our business that may result in substantial claims against us relating to handling, storage or disposal.
  • If we are not able to manage our growth strategy or if we experience difficulties identifying or integrating companies or technologies we may acquire, our operating results may be adversely affected.
  • Our acquisition of Alere’s Triage® and BNP Businesses presents certain risks to our business and operations
  • We may need to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.
  • Our debt, deferred and contingent payment obligations could materially adversely affect our financial condition and results of operations.
  • Our business could be negatively affected by the loss of or the inability to hire key personnel.
  • We are subject to, and may in the future become subject to, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us.
  • We are exposed to business risk which, if not covered by insurance, could have an adverse effect on our results of operations.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability.
  • Some provisions of our charter documents and Delaware law may make takeover attempts difficult, which could depress the price of our stock and inhibit our stockholders’ ability to receive a premium price for their shares.
Management Discussion
  • Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31. Fiscal year 2020 was 53 weeks and fiscal year 2019 was 52 weeks.
Content analysis
H.S. freshman Avg
New words: accident, adjoining, administer, administered, advantage, Agency, anterior, antidumping, assumption, backup, bad, began, Biochemistry, Biology, Biosite, Brexit, burden, capacity, cardiometabolic, Carlsbad, cease, CGMP, childcare, collaboration, complicate, conflict, Congo, Conservation, constrain, contact, context, contributor, Cornell, counter, countervailing, curb, curtail, Dame, debarment, deliverable, Democratic, Digital, diminished, disability, disaster, distancing, dramatic, drove, duration, ensuing, EUA, exacerbate, expedite, explore, export, extremely, factor, fellowship, Ferenczy, frequency, FTC, gold, half, heightened, hinder, homework, Hort, hygiene, ill, induce, ineffective, Inovise, IVDR, lawyer, light, lockdown, Massey, Michelle, misleading, mission, Nanosphere, nasal, NIH, Notre, nucleocapsid, occupational, online, optimal, outbreak, outfitting, pandemic, Park, population, prescription, proactively, prove, quarantine, ramp, Ranalli, reconsider, recordkeeping, Recovery, rejected, Relatedly, remittitur, remotely, Republic, requisitioned, resorption, restrained, restraint, resume, retaliatory, retention, retroactive, revoked, Rochester, Roswell, Rutherford, safeguard, sandwich, sanitizing, Sci, se, sharply, shelter, shutdown, side, situation, slowdown, sort, statute, stoppage, stricter, student, succeed, sudden, switching, talented, Tamara, tantalum, tie, tin, Transcriptase, travel, tuition, tungsten, UCLA, unbilled, uncertainty, unemployment, unrest, unsuitable, upgrade, vaccination, virtually, vital, waste, William, workforce, Zealand
Removed: Abney, accomplish, achieved, adjustment, agree, Agriculture, Alan, amend, amounted, amplify, AmpliVue, analyst, analyzed, assigned, assigning, ASU, avian, Bachelor, Banking, bolstered, Borkar, borrowed, breached, Bulletin, buying, calculating, carry, cassette, Channel, Chartered, choosing, close, closed, codified, Commerce, commercialize, compare, compute, consecutive, consumption, contradictory, ConvaTec, corruption, declared, declaring, declined, defaulted, desired, dilution, discretion, dispose, diversify, divided, drop, economically, efficiently, eliminate, encountered, encryption, estimation, exercisable, FASB, fire, Florida, fluorescence, flux, focused, France, fundamental, furniture, Gelband, gene, hazard, heading, holder, impacting, impossible, inadequacy, incidence, indemnification, indemnified, indenture, inflation, inherently, interim, introduced, Jr, June, Kingdom, KPMG, leaving, lessee, leveraging, liquidation, mandatory, mature, Michael, Michigan, mitigated, Morgan, moved, Mumbai, negotiated, nonperformance, observation, occurrence, orderly, pathogen, precautionary, preceding, prepay, prevail, prevailing, principle, provisional, PSS, Ratan, receiving, recoup, reducing, refinancing, reform, regulating, reliably, renegotiating, representing, restructuring, revaluation, reversal, SAB, safe, Scholar, shareholder, sharing, Simplifying, solid, Spain, subsidiary, surrender, tangible, territorial, transition, unanticipated, unclear, undertaken, undistributed, unpaid, unpredictably, unrelated, valuable, veterinary, VP, VWAP, whichever, window